Therapies for Breast and Prostate Cancer

Therapies for Breast and Prostate Cancer is organized by University of Pittsburgh Medical Center (UPMC). 

Release Date: 10/18/2017
Last Modified: 4/7/2020
Expires: 10/19/2020

Accreditation:
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.1) continuing education units (CEU) which are equivalent to 1.0 contact hour.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Educational objectives:
Upon completion of this activity, participants should be able to: 
• Describe data supporting early chemotherapy in metastatic prostate cancer
• Recognize selection of patients for early chemotherapy for metastatic prostate cancer
• Recognize risk factors for chemotherapy toxicity
• Describe the history of endocrine treatment
• Follow the differences in pre vs post-menopausal breast cancer
• Recognize recent updates in hormonal therapy

Additional details will be posted as soon as information is available.